gemcitabine has been researched along with Adverse Drug Event in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (23.73) | 29.6817 |
| 2010's | 38 (64.41) | 24.3611 |
| 2020's | 7 (11.86) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Bhardwaj, TR; Gaba, T; Malhotra, M; Matharoo, S; Rawal, RK; Sharma, R; Singla, N | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| Acar, R; Akcan, E; Aykan, MB; Erturk, I; Karadurmus, N; Yildiran, GS | 1 |
| Cogen, AL; Kovacs, LD; O'Donoghue, M | 1 |
| Basch, E; Dueck, A; Johansen, C; Lindberg, H; Pappot, H; Taarnhøj, GA | 1 |
| Bendell, J; Feeney, K; Gracián, AC; Hecht, JR; Hung, A; Lee, MA; Lin, Y; Lonardi, S; Muñoz, A; Ryoo, BY; Wainberg, ZA | 1 |
| Ando, M; Ando, Y; Ebata, T; Inada-Inoue, M; Maeda, O; Matsuoka, A; Mitsuma, A; Miyai, Y; Mizuno, T; Morita, S; Nagino, M; Shimokata, T; Sugishita, M; Takano, Y; Urakawa, H | 1 |
| Brede, CM; Broekhuizen, HT; Busman, RD; Kuipers, SK; Kuperus, JM; Lane, BR; Noyes, SL; Tobert, CM | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Arroyo-Conde, C; Casanova-Martinez, C; González-Costas, S; Piñeiro-Corrales, G; Romero-Ventosa, EY | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Zhang, Z | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Chandler, D; Grossman, A; Hanau, A; Hatfield, M; Lonshteyn, A; Sharma, A; Weycker, D | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Ariyoshi, K; Eto, T; Okadome, M; Saito, T; Shimamoto, K; Tomita, Y | 1 |
| Dong, S; Li, WT; Peng, WJ; Ye, XD; Yuan, Z | 1 |
| Ito, K; Kaiho-Sakuma, M; Kurosawa, H; Nagai, T; Nagase, S; Niikura, H; Otsuki, A; Otsuki, T; Shiga, N; Shigeta, S; Takano, T; Tanaka, S; Tokunaga, H; Toyoshima, M; Tsuji, K; Utsunomiya, H; Yaegashi, N; Yamaguchi, T | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Kojo, M; Morodomi, Y; Seto, T; Shimokawa, M; Shiraishi, Y; Takenaka, T; Takenoyama, M; Toyokawa, G; Toyozawa, R; Yamaguchi, M | 1 |
| Chang, Y; Fu, XR; Li, L; Li, X; Qiu, YJ; Sun, ZC; Wang, R; Wang, XH; Wu, JJ; Zhang, C; Zhang, L; Zhang, MZ | 1 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Barlesi, F; Besse, B; Cappuzzo, F; Carcereny, E; Felip, E; Ferry, D; Garcia-Ribas, I; Mazieres, J; Novello, S; Reck, M; Santoro, A; Scagliotti, G; Soria, JC; von Pawel, J; Zalcman, G | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Kaniwa, N | 1 |
| Besse, B; Blackhall, F; Brandén, E; de Petris, L; Edsgärd, D; Gréen, H; Hasmats, J; Koyi, H; Kupershmidt, I; Lewensohn, R; Lindgren, A; Lundeberg, J; Peterson, C; Vikingsson, S | 1 |
| Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN | 1 |
| Chao, Y; Chen, JS; Chen, LT; Chen, MH; Chiang, NJ; Hsu, C; Huang, SF; Shan, YS; Shen, YY; Tsou, HH; Yeh, TS | 1 |
| Guo, J; Han, X; Hu, GF; Liu, LY; Tang, N; Wang, X; Wang, Y; Wang, ZH; Zhang, QQ | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Fridley, BL; Jenkins, G; Schaid, DJ; Wang, L | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Saif, MW | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Ebrahim, MA; Halim, A; Saleh, Y | 1 |
| Carlson, H; Lenzi, R; Raber, MN; Varadhachary, GR | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H | 1 |
| Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Durand, JP; Goldwasser, F; Mir, O; Perkins, G; Ropert, S | 1 |
| Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Miyauchi, Y; Shimamoto, K; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| Fukuoka, M; Kashii, T; Kato, T; Matsui, K; Nakagawa, K; Nakanishi, Y; Negoro, S; Sugiura, T; Takada, M; Takada, Y; Uejima, H; Yamamoto, N | 1 |
| Blankenburg, T; Chemaissani, A; Guetz, S; Laier-Groeneveld, G; Reck, M; Schneider, CP; Schuette, W; Virchow, JC; von Weikersthal, LF | 1 |
| González, C; Morís, G; Ribacoba, R | 1 |
| Aydiner, A; Cakan, A; Cikrikcioglu, S; Dilege, S; Goksel, T; Gurses, A; Kiyik, M; Kosar, F; Turna, A; Yazar, A | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Ahn, E; Flores, A; Lopes, G; Quesada, J; Ribeiro, A; Rocha-Lima, CM | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Alvarez, I; Burris, H; Chow, S; Dragovich, T; Gordon, M; Green, S; Loehrer, P; Obregon, Y; Stratton, S; Von Hoff, DD | 1 |
5 review(s) available for gemcitabine and Adverse Drug Event
| Article | Year |
|---|---|
Chemotherapy-Induced Pseudocellulitis Without Prior Radiation Exposure: A Systematic Review.
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male | 2023 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Deoxycytidine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Genomics; Glucuronosyltransferase; HLA Antigens; Humans; International Cooperation; Irinotecan; Japan; Pharmacogenetics; Precision Medicine; Prodrugs; Product Surveillance, Postmarketing | 2015 |
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
24 trial(s) available for gemcitabine and Adverse Drug Event
| Article | Year |
|---|---|
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Intra-arterial infusion chemotherapy for advanced non-small-cell lung cancer: preliminary experience on the safety, efficacy, and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2016 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2016 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin | 2013 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2006 |
Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Demography; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyridines; Salvage Therapy; Survival Analysis | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
30 other study(ies) available for gemcitabine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Design, synthesis and ex vivo evaluation of colon-specific azo based prodrugs of anticancer agents.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Line, Tumor; Colon; Colonic Neoplasms; Drug Design; Drug-Related Side Effects and Adverse Reactions; Feces; Humans; Inhibitory Concentration 50; Mesalamine; Prodrugs; Rats | 2013 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours.
Topics: Adult; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Observational Studies as Topic; Oxaliplatin; Paclitaxel | 2022 |
Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Denmark; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prognosis; Prospective Studies; Quality of Life; Surveys and Questionnaires; Urinary Bladder Neoplasms | 2020 |
Chemotherapy for biliary tract cancer: real-world experience in a single institute.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies | 2020 |
Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Tapering; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Reported Outcome Measures; Prevalence; Symptom Assessment; Urinary Bladder Neoplasms | 2021 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Recombinant Proteins; Thymoma; Thymus Neoplasms; Uganda | 2019 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Hospitalization; Humans; Incidence; Induction Chemotherapy; Length of Stay; Retrospective Studies; Risk; Thrombocytopenia; United States | 2019 |
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2014 |
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leiomyosarcoma; Middle Aged; Sarcoma, Endometrial Stromal; Taxoids; Uterine Neoplasms | 2014 |
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinorelbine | 2014 |
Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Deoxycytidine; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Polyethylene Glycols; Remission Induction | 2014 |
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Thrombocytopenia | 2016 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Gene Expression; Genetic Variation; Humans; Models, Statistical; Pharmacogenetics | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Pulmonary toxicity associated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Pneumonia; Severity of Illness Index | 2010 |
Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2011 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids | 2013 |
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangitis; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Peripheral Nervous System Diseases; Retrospective Studies; Sarcopenia; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |
Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Renal Insufficiency; Urologic Neoplasms; Urothelium | 2013 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.
Topics: Antineoplastic Agents; Brain Diseases; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms | 2007 |